Here, we report data from the first-in-human, phase I study of MVX-ONCO-1, a patient-specific cancer immunotherapy combining irradiated autologous tumor cells and encapsulated allogeneic cells producing GM-CSF. Here, CSF2 is linked to neoplasm.